Nova Eye Medical (EYE) Discussion, page-2480

I would personally temper my expectations here a little on near term profitability.

Do we know which form of profitability that the company is referring to? I prefer NPAT because it is what is available to shareholders. Companies however typically prefer EBITDA because it is easier to generate.

EBITDA breakeven is possible on a monthly basis towards the end of the calendar year but NPAT breakeven looks like it is futher six months away to me and will require maybe up to $35m of revenue to achieve.

If I had to guess I would say we are probably looking at a $3-4m NPAT loss in the second half of FY24, versus a $5.6m loss in the first half.

The good news for the patient is that if/when it becomes apparent that NPAT profitability is guaranteed then I think we can see the big re-rate from 2x sales to 5x sales.